Logo

Bio-Rad to Place $250M in Private Notes

May 19, 2009

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories said today that it plans to offer $250 million in a private overseas debt offering to raise funds for working capital, and general corporate purposes, including acquisitions.

The company said that the $250 million aggregate senior subordinated notes will be offered only to qualified institutional buyers and may not be sold inside the United States.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.